What is Rona Therapeutics?
Founded in 2021, Rona Therapeutics is a specialized biopharmaceutical firm dedicated to the development of nucleic acid therapeutics. The company's core competency lies in its proprietary extrahepatic delivery platform, which enables the treatment of complex diseases that have historically been considered undruggable by conventional modalities. Its current clinical portfolio includes advanced siRNA candidates targeting hypercholesteremia and mixed dyslipidemia, alongside a robust pipeline for neurodegenerative disorders such as ALS and Alzheimer's disease. By prioritizing improved tolerability and extended dosing intervals, the company aims to redefine the standard of care for cardiovascular, metabolic, and renal health.
How much funding has Rona Therapeutics raised?
Rona Therapeutics has raised a total of $68M across 1 funding round:
Series A
$68M
Series A (2024): $68M with participation from BioTrack Capital and Lilly Asia Ventures
Key Investors in Rona Therapeutics
BioTrack Capital
A dedicated healthcare venture capital firm focused on building and incubating innovative life science companies, with a specific emphasis on discovering breakthrough business models in the Chinese biotech sector.
Lilly Asia Ventures
A leading biomedical venture capital firm with a global footprint, specializing in partnering with exceptional entrepreneurs to develop breakthrough products that improve human health.
What's next for Rona Therapeutics?
With the successful closure of this funding round, Rona Therapeutics is well-positioned to advance its lead assets through critical IND-enabling stages and clinical trials. The strategic allocation of capital will likely focus on scaling the company's extrahepatic delivery platform, allowing for broader therapeutic applications beyond liver-targeted treatments. As the firm continues to build out its clinical infrastructure, investors will be monitoring the progress of its metabolic assets and the potential for future strategic partnerships. The company's ability to maintain long-term knockdown potency will be a primary indicator of its competitive advantage in the crowded siRNA landscape.
See full Rona Therapeutics company page
